Waaxda Caalamiga ah

Abriil 25, 2025, InnoCare Pharma waxay ku dhawaaqday in daawada cusub ee ka hortagga pan-TRK zurletrectinib (ICP-723) ay siisay dib u eegis mudnaan leh Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA), oo aqbashay Codsiga Daawada Cusub (NDA) ee z...Akhriso wax dheeraad ah»

Abriil 25, 2025, Innovent Biologics waxay ku dhawaaqday in Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) uu ansixiyay Codsiga Daawada Cusub (NDA) ee limertinib inuu yahay daaweynta ugu horreysa ee bukaanada qaangaarka ah ee qaba kansarka sambabka ee unugyada yaryar ee aan caadiga ahayn (NSCLC) ee maxalliga ah...Akhriso wax dheeraad ah»

Abriil 23, Penpulimab-ka Akeso wuxuu Maamulka Cuntada iyo Dawooyinka u ansixiyay cisplatin ama carboplatin iyo gemcitabine si loogu daaweeyo dadka waaweyn ee qaba kansarka nasopharyngeal ee aan keratinizing (NPC) ee soo noqnoqda ama soo noqnoqda. FDA waxay sidoo kale ansixisay penpulimab-kcqx inay tahay sin...Akhriso wax dheeraad ah»

Maarso 16, 2025, Akeso waxay ku dhawaaqday in antibody-geeda cusub ee iskiis u horumarsan ee ka hortagga PD-1 monoclonal antibody, penpulimab, ay si rasmi ah u ansixisay Maamulka Waxsoosaarka Caafimaadka Qaranka (NMPA) si loogu daaweeyo kansarka sanbabada ee soo noqnoqda ama metastatic (NPC) oo isku dhafan ...Akhriso wax dheeraad ah»

Abriil 24, 2025, GenFleet Therapeutics waxay ku dhawaaqday in Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) uu ogolaaday isticmaalka cusub ee daawada (IND) ee baaritaanka ee GFH375/VS-7375, oo ah daawo afka laga qaato oo lagu magacaabo KRAS G12D (ON/OFF), si loogu sameeyo tijaabo caafimaad oo lagu daaweynayo bukaanada burooyinka adag ee horumarsan ee qaba isbeddelka KRAS G12D. Daraasadda...Akhriso wax dheeraad ah»

Abriil 17, 2025, Hansoh Pharmaceutical waxay ku dhawaaqday in daawada isku-darka ee B7-H3 ee kooxda iska soo saartay ee la beegsanayo antibody-drug conjugate (ADC) HS-20093 ee loogu talagalay duritaanka ay heshay oggolaansho lagu daro Daawaynta Degdegga ah ee ay u qoondaysay Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) ee Shiinaha, ...Akhriso wax dheeraad ah»

Abriil 15, 2025, InnoCare Pharma waxay ku dhawaaqday in Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) ay aqbashay Codsiga Daawada Cusub (NDA) ee jiilka cusub ee pan-TRK inhibitor zurletrectinib (ICP-723) si loogu daaweeyo dadka waaweyn iyo kuwa qaangaarka ah...Akhriso wax dheeraad ah»

Dhawaan, GenFleet waxay ku dhawaaqday xogtii ugu dambeysay ee wejiga labaad ee daraasadda KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) oo ay weheliso cetuximab oo loogu talagalay daaweynta kansarka sambabka ee unugyada yaryar (NSCLC), oo ah warbixin kooban oo goor dambe ah oo ku saabsan bandhigga afka ah ee Shirka Kansarka Sambabka ee Yurub ee 2025...Akhriso wax dheeraad ah»

PLB1004, oo ay soo saartay Beijing Avistone Biotechnology Co., Ltd., waa dawo badbaado leh, aad loo xushay, oo waxtar leh oo aan dib loo celin karin oo soo-dhoweeyaha koritaanka epidermal-ka ee tyrosine kinase inhibitor (EGFR-TKI) oo loo adeegsado daaweynta kansarka sambabada unugyada yaryar (NSCLC). Abriil 9, 2025, Badeecadaha Caafimaadka Qaranka ayaa...Akhriso wax dheeraad ah»

Maarso 13, 2025, joornaalka caalamiga ah ee ugu sarreeya Nature Medicine wuxuu daabacay tijaabadii MediLink ee B7-H3 ee bartilmaameedsanaysa isku-darka daawada antibody-ga (ADC) ee YL201 Wajiga 1/1b. Tijaabadii waxaa ku jiray qayb kor u kaca qiyaasta (wajiga 1) iyo qayb ballaarinta qiyaasta (wajiga 1b). Wadarta 312 bukaan ayaa laga diiwaangeliyey...Akhriso wax dheeraad ah»

Maarso 21, 2025, Immunofoco waxay ku dhawaaqday in daaweynta unugyada CAR-T ee si madax-bannaan loo sameeyay ee bartilmaameedsanaysa EpCAM, IMC001, ay oggolaansho siisay Xarunta Qiimaynta Daawada (CDE) oo hoos timaada Maamulka Badeecadaha Caafimaadka Qaranka (NMPA) ee Shiinaha markii labaad ee Baaritaan Cusub oo Cusub...Akhriso wax dheeraad ah»

Maarso 31, 2025, Innovent Biologics ayaa ku dhawaaqday in Xarunta Qiimaynta Daawada (CDE) ee Maamulka Badeecadaha Caafimaadka Qaranka ee Shiinaha (NMPA) ay siisay Magacaabista Daaweynta Degdegga ah (BTD) ee IBI363, oo ah borotiin isku-darka unugyada difaaca jirka ee heerka koowaad ee PD-1/IL-2α-bias, oo ah daaweyn hal-hal ah oo loogu talagalay...Akhriso wax dheeraad ah»